CAPR - NASDAQ
Capricor Therapeutics, Inc.
$27.64
+1.1%Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
At a Glance
Live Snapshotcapr
Cash and Cash Equivalents
Last Annual Value
287.85M
3-Year CAGR
211%
5-Year CAGR
55%
10-Year CAGR
48%
Capricor Therapeutics, Inc. Competitors Analysis of Cash and Cash Equivalents
| Company | Cash and Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Capricor Therapeutics, Inc. NASDAQ:CAPR | 287.85M | 169.6% | 52.5% | 56.8% | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 63.00M | -19.7% | -14.2% | N/A | |
 Vanda Pharmaceuticals Inc. NASDAQ:VNDA | 84.85M | -14.5% | 10.3% | 7.7% | |
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 70.04M | -21.1% | -21.1% | 19.3% | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 124.09M | 53.0% | 10.3% | N/A | |
 Alector, Inc. NASDAQ:ALEC | 65.80M | -4.1% | -27.5% | 2.6% | |
 Candel Therapeutics, Inc. NASDAQ:CADL | 119.73M | 50.1% | 7.7% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 50.50M | -14.4% | -25.3% | N/A | |
 Editas Medicine, Inc. NASDAQ:EDIT | 146.65M | 5.8% | -6.3% | -2.3% | |
 Allogene Therapeutics, Inc. NASDAQ:ALLO | 51.69M | -14.7% | -21.5% | N/A | |
 Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 230.91M | -7.5% | -9.0% | 58.5% |
Capricor Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your CAPR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.